Yoshino T - Search Results

1

Reply to `Comment on `Clinical significance of BRAF non-V600E mutations on the therapeutic effects of anti-EGFR monoclonal antibody treatment in patients with pretreated metastatic colorectal cancer: the Biomarker Research for anti-EGFR monoclonal Antibodies by Comprehensive Cancer genomics (BREAC) study''.

Shinozaki E, Yoshino T, Tsuchihara K. Shinozaki E, et al. Among authors: yoshino t. Br J Cancer. 2018 May;118(9):1278-1279. doi: 10.1038/s41416-018-0040-y. Epub 2018 Mar 22. Br J Cancer. 2018. PMID: 29563632 Free PMC article. No abstract available.

2

A phase I escalating single-dose and weekly fixed-dose study of cetuximab pharmacokinetics in Japanese patients with solid tumors.

Shirao K, Yoshino T, Boku N, Kato K, Hamaguchi T, Yasui H, Yamamoto N, Tanigawara Y, Nolting A, Yoshino S. Shirao K, et al. Among authors: yoshino s, yoshino t. Cancer Chemother Pharmacol. 2009 Aug;64(3):557-64. doi: 10.1007/s00280-008-0904-6. Epub 2009 Jan 24. Cancer Chemother Pharmacol. 2009. PMID: 19169687 Clinical Trial.

3

[Two cases of KRAS wild-type unresectable or recurrent colorectal cancer effectively treated by cetuximab after progression of prior chemotherapy].

Yoda Y, Yoshino T, Kadowaki S, Bando H, Okano S, Fukushima H, Fuse N, Tahara M, Doi T, Ohtsu A. Yoda Y, et al. Among authors: yoshino t. Gan To Kagaku Ryoho. 2009 Jun;36(6):1003-6. Gan To Kagaku Ryoho. 2009. PMID: 19542725 Japanese.

4

Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.

Ogasawara N, Bando H, Kawamoto Y, Yoshino T, Tsuchihara K, Ohtsu A, Esumi H. Ogasawara N, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2011 Jan;41(1):52-6. doi: 10.1093/jjco/hyq151. Epub 2010 Aug 9. Jpn J Clin Oncol. 2011. PMID: 20696815

5

Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.

Bando H, Tsuchihara K, Yoshino T, Kojima M, Ogasawara N, Fukushima H, Ochiai A, Ohtsu A, Esumi H. Bando H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2011 Feb;41(2):239-44. doi: 10.1093/jjco/hyq216. Epub 2010 Nov 26. Jpn J Clin Oncol. 2011. PMID: 21113056

6

[Clinical significance and the handling of KRAS testing on metastatic colorectal cancer].

Kawamoto Y, Yoshino T. Kawamoto Y, et al. Among authors: yoshino t. Nihon Rinsho. 2011 Apr;69 Suppl 3:346-50. Nihon Rinsho. 2011. PMID: 22213982 Review. Japanese. No abstract available.

7

Clinical outcome of Japanese metastatic colorectal cancer patients harbouring the KRAS p.G13D mutation treated with cetuximab + irinotecan.

Bando H, Yoshino T, Yuki S, Shinozaki E, Nishina T, Kadowaki S, Yamazaki K, Kajiura S, Tsuchihara K, Fujii S, Yamanaka T, Ohtsu A. Bando H, et al. Among authors: yoshino t. Jpn J Clin Oncol. 2012 Dec;42(12):1146-51. doi: 10.1093/jjco/hys160. Epub 2012 Oct 15. Jpn J Clin Oncol. 2012. PMID: 23071293

8

[Predictive biomarkers for anti-EGFR antibodies].

Bando H, Yoshino T. Bando H, et al. Among authors: yoshino t. Gan To Kagaku Ryoho. 2012 Nov;39(11):1618-25. Gan To Kagaku Ryoho. 2012. PMID: 23152013 Review. Japanese.

9

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.

Doi T, Muro K, Yoshino T, Fuse N, Ura T, Takahari D, Feng HP, Shimamoto T, Noguchi K, Ohtsu A. Doi T, et al. Among authors: yoshino t. Cancer Chemother Pharmacol. 2013 Sep;72(3):643-52. doi: 10.1007/s00280-013-2240-8. Epub 2013 Aug 7. Cancer Chemother Pharmacol. 2013. PMID: 23921573 Free PMC article. Clinical Trial.

10

Simultaneous identification of 36 mutations in KRAS codons 61 and 146, BRAF, NRAS, and PIK3CA in a single reaction by multiplex assay kit.

Bando H, Yoshino T, Shinozaki E, Nishina T, Yamazaki K, Yamaguchi K, Yuki S, Kajiura S, Fujii S, Yamanaka T, Tsuchihara K, Ohtsu A. Bando H, et al. Among authors: yoshino t. BMC Cancer. 2013 Sep 3;13:405. doi: 10.1186/1471-2407-13-405. BMC Cancer. 2013. PMID: 24006859 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,111 results

Search Page

Filters